Physician profile
Michael J Ackerman
NPI 1104802032
$46,482.81
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,388 · 2021: $22K · 2022: $2,441 · 2023: $4,724 · 2024: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $4,405 · Travel and Lodging: $2,071 · Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,125.00 |
| Consulting Fee | $4,405.00 |
| Travel and Lodging | $2,070.71 |
| Food and Beverage | $624.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24,527.94 | 2021-2022 | |
| Boston Scientific Corporation | $6,796.77 | 2024 | |
| Genentech USA, INC. | $4,710.95 | 2024 | Xolair |
| Biomarin Pharmaceutical INC. | $4,500.00 | 2023 | |
| Biotronik INC. | $3,112.97 | 2019 | |
| Daiichi Sankyo INC. | $1,275.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $993.81 | 2024 | |
| Sanofi-Aventis U.S. LLC | $300.00 | 2021 | |
| Medtronic, INC. | $140.00 | 2023 | Cobalt Dr Mri Surescan |
| Stryker Corporation | $84.14 | 2023 | Procuity |
| Pfizer INC. | $41.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.